Alternatives to SurpassMD

Four flat, posted price points across semaglutide and three tirzepatide formats, with a written promise the cost won't climb with your dose — a real step up in clarity from what we found last check — undercut by a state list it still won't publish.

• $15/mo cheaper than SurpassMD
• scores 75/100 against SurpassMD's 34

A low-entry, all-in compounded program with both molecules and a clean cancel-anytime policy — appealing if the starting price holds, but the ongoing rate isn't published and the outcome claims are unverified marketing.

• $15/mo cheaper than SurpassMD
• scores 76/100 against SurpassMD's 34

Shapely is the first provider in this batch that takes insurance — it says it is in network with Medicare and major PPO plans, and quotes brand-name co-pays of "typically $25 per month". That genuinely changes the arithmetic for anyone with coverage. What has to be read carefully is what the membership buys: $99 a month, $49 for the first, and it explicitly does not include medications or labs. So the compounded prices, $99 for semaglutide and $166 for tirzepatide, sit on top of the membership rather than replacing it.

• $15/mo cheaper than SurpassMD
• offers FDA-approved brand pens, not just compounded
• scores 50/100 against SurpassMD's 34

Pepti publishes the lowest semaglutide price in this entire roster — $99 a month, flat at every titration dose, with the medication, physician review, shipping, refill management and unlimited messaging with your prescribing doctor all inside it. Tirzepatide is $199 on the same all-in, flat-at-every-dose basis. That number is low enough to deserve skepticism, so it is worth saying exactly where it comes from: Pepti states it on a dedicated cost page, repeats it in its FAQ ('we keep pricing flat and transparent at $99/mo all-in'), and prices the comparison against Hims, Henry Meds and Mochi on the same page. It names two prescribing physicians and says its medication is compounded by FDA-registered 503A or 503B pharmacies, though it never names which. The real limits are reach and format: it ships to 36 states rather than 50, it is cash-pay only and bills no insurance, and its needle-free oral GLP-1/GIP drops cost $349 — well above its own injection.

• $15/mo cheaper than SurpassMD
• scores 58/100 against SurpassMD's 34

Physician-founded and genuinely cheap, with both molecules in a lozenge or a shot and a free MD visit — but a February 2026 FDA misbranding letter is a caveat a mother should read before signing up.

• scores 80/100 against SurpassMD's 34

The widest menu on our roster — injections, sublingual lozenges, daily drops, four brand-name pens and the approved oral GLP-1 — with three compounding pharmacies named, a flat price at any dose, and cancellation terms among the most restrictive we have read.

• offers FDA-approved brand pens, not just compounded
• scores 76/100 against SurpassMD's 34

Now confirmed to publish real GLP-1 prices — compounded semaglutide from $199, tirzepatide from $349, plus brand options — right on its products page, no consult required, contrary to what an earlier check found.

• offers FDA-approved brand pens, not just compounded
• scores 76/100 against SurpassMD's 34

Compounded semaglutide from $99 a month and tirzepatide from $149, with no membership fee, a dietitian attached to every plan, and a genuinely deep FAQ library that has a whole section on pregnancy — rarer here than it should be. Read two promises carefully before you sign. Every page says 'No price increases — ever', while the billing consent you actually click to accept reserves Harbor's right to change pricing on thirty days' notice. And 'No results? No charge' is a twelve-month guarantee with eight conditions attached, including staying enrolled for all twelve months and taking no other weight-loss medication in the year before you start. Every price on the site is a floor, so what you pay after the first month is not published anywhere.

• $15/mo cheaper than SurpassMD
• scores 57/100 against SurpassMD's 34

A rare needle-free option at true price parity — $79/mo semaglutide or $133/mo tirzepatide, injectable or oral, same price — though NuuVim frames it as a new-patient rate with an unpublished refill tier, and its 50-state coverage claim couldn't be confirmed on its own live site this pass.

• $35/mo cheaper than SurpassMD
• offers FDA-approved brand pens, not just compounded
• scores 37/100 against SurpassMD's 34